Zydus Cadila receives final approval for Cyproheptadine Hydrochloride tablets USP

23 May 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Cyproheptadine Hydrochloride Tablets USP, 4 mg. It is an antihistamine used to relieve allergy symptoms such as watery eyes, running nose, itching eyes or nose, sneezing, hives, and itching.  The drug will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.  The group now has around 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

903.60 24.35 (2.77%)
03-Feb-2026 10:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1698.65
Dr. Reddys Lab 1230.65
Cipla 1335.95
Zydus Lifesciences 903.60
Lupin 2171.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×